中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
2021 No.11
Theme Issue: Mechanism and clinical practice of drug-induced liver injury
Executive Chief Editor: Yang Changqing  
Department of Gastroenterology, Tongji Hospital Affiliated to Tongji University
Cover Content

 Previous Issue | Next Issue 

Display Method:
Editorial
Drug-induced liver injury: Advances and confusions in treatment
Shuai CHEN, Changqing YANG
2021, 37(11): 2505-2509. DOI: 10.3969/j.issn.1001-5256.2021.11.001
Abstract(1312) HTML (226) PDF (2004KB)(347)
Abstract:
Drug-induced liver injury (DILI) is one of the most common and serious adverse drug reactions and can lead to acute liver failure and even death in severe cases. The pathogenesis of DILI has not been fully clarified, and there is significant individual difference. There is no effective treatment for...
Discussions by experts
Epidemiology of drug-induced liver injury
Xiaoyun LI, Jieting TANG
2021, 37(11): 2510-2514. DOI: 10.3969/j.issn.1001-5256.2021.11.002
Abstract(1671) HTML (442) PDF (1902KB)(423)
Abstract:
The incidence rate of drug-induced liver injury (DILI) is increasing year by year, and DILI has become one of the common liver diseases in clinical practice and has attracted the attention of the whole world. It is known that a variety of drugs, including Chinese herbal medicine and dietary suppleme...
Pathogenesis of drug-induced liver injury: Current understanding and future needs
Yuecheng YU, Chengwei CHEN
2021, 37(11): 2515-2524. DOI: 10.3969/j.issn.1001-5256.2021.11.003
Abstract(2440) HTML (254) PDF (4898KB)(453)
Abstract:
The risk factors for drug-induced liver injury (DILI) involve host factors (including general non-genetic factors and idiosyncratic genetic and immune factors), drug-related factors, and environmental factors. The pathogenesis of DILI can be classified as intrinsic (or direct) hepatotoxicity, idiosy...
Clinical manifestations and typing of drug-induced liver injury
Wanna YANG, Wen XIE
2021, 37(11): 2525-2529. DOI: 10.3969/j.issn.1001-5256.2021.11.004
Abstract(2258) HTML (478) PDF (1907KB)(338)
Abstract:
Drug-induced liver injury (DILI) is one of the most common and severe adverse drug reactions in humans, which may lead to liver failure and even death in some patients. Liver injury caused by different drugs has various clinical manifestations and severities, and most patients with DILI have no symp...
Pathological features and pathological diagnosis of drug-induced liver injury
Yongfeng YANG
2021, 37(11): 2530-2533. DOI: 10.3969/j.issn.1001-5256.2021.11.005
Abstract(1323) HTML (284) PDF (2065KB)(244)
Abstract:
Based on liver histology, drug-induced liver injury (DILI) is classified as various pathological types of inflammatory necrosis, cholestasis, fatty degeneration and fatty liver disease, vascular injury, and minimal lesion. Histopathological examination is required for further differential diagnosis ...
Clinical features of drug-induced liver failure and related diagnosis and treatment strategies
Rongtao LAI, Qing XIE
2021, 37(11): 2534-2538. DOI: 10.3969/j.issn.1001-5256.2021.11.006
Abstract(764) HTML (190) PDF (1937KB)(244)
Abstract:
The incidence of drug-induced liver injury (DILI) has risen considerably in recent years. Drug-induced liver failure tends to have severe conditions, limited therapeutic strategy, and a high mortality rate and should thus be taken seriously by clinicians. N-acetyl-p-aminophenol is the most common ca...
Academic contention
Patients with chronic hepatitis B virus infection in the indeterminate phase may benefit from antiviral therapy
Jinghang XU, Xiaoyuan XU, Yanyan YU
2021, 37(11): 2539-2540. DOI: 10.3969/j.issn.1001-5256.2021.11.007
Abstract(551) HTML (91) PDF (1855KB)(146)
Abstract:
Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy
Jingyue WANG, Yuan HUANG
2021, 37(11): 2541-2541. DOI: 10.3969/j.issn.1001-5256.2021.11.008
Abstract(526) HTML (86) PDF (1875KB)(93)
Abstract:
Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
Yingying JIANG, Shan REN, Xinyue CHEN, Sujun ZHENG
2021, 37(11): 2543-2544. DOI: 10.3969/j.issn.1001-5256.2021.11.009
Abstract(483) HTML (80) PDF (1862KB)(80)
Abstract:
Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
Jun JIANG, Fuzhong WU, Deyang WANG
2021, 37(11): 2545-2545. DOI: 10.3969/j.issn.1001-5256.2021.11.010
Abstract(486) HTML (131) PDF (1842KB)(77)
Abstract:
How far are we from the "Treat all" era of antiviral therapy for chronic hepatitis B
Yang DING, Xiaoguang DOU
2021, 37(11): 2546-2547. DOI: 10.3969/j.issn.1001-5256.2021.11.011
Abstract(598) HTML (107) PDF (1860KB)(106)
Abstract:
Guidelines
An excerpt of diagnosis, evaluation, and management of ascites and hepatorenal syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases
Jiaxuan HU, Tao HAN
2021, 37(11): 2548-2549. DOI: 10.3969/j.issn.1001-5256.2021.11.012
Abstract(807) HTML (213) PDF (1857KB)(291)
Abstract:
An excerpt of EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update
Yue ZHANG, Xingyang SU, Jingyi XIE, Jue PAN, Fanpu JI
2021, 37(11): 2550-2553. DOI: 10.3969/j.issn.1001-5256.2021.11.013
Abstract(1083) HTML (363) PDF (3005KB)(298)
Abstract:
An excerpt of Budd-Chiari syndrome: Consensus guidance of the Asian Pacific Association for the Study of the Liver (APASL)
Xueying WANG, Wentao XU, Xiaowei DANG, Xingshun QI
2021, 37(11): 2555-2557. DOI: 10.3969/j.issn.1001-5256.2021.11.014
Abstract(615) HTML (106) PDF (2151KB)(178)
Abstract:
Original articles_Liver fibrosis and liver cirrhosis
Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease
Pinhua LI, Xudong LIU, Lu HUANG, Humin ZHU, Tiexiong WU, Huazhen PANG
2021, 37(11): 2558-2561. DOI: 10.3969/j.issn.1001-5256.2021.11.015
Abstract(723) HTML (167) PDF (1938KB)(55)
Abstract:
Objective To investigate whether the progression of liver fibrosis affects endothelial function in patients with nonalcoholic fatty liver disease (NAFLD), and to early identify the warning of cardiovascular diseases caused by endothelial dysfunction by liver fibrosis progression. Methods A total of ...
Therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism
Xuling LIU, Guangyue YANG, Wei ZHANG, Tiantian SUN, Wenting MA, Liu WU, Dongying XUE, Cheng LIU, Le TAO
2021, 37(11): 2563-2568. DOI: 10.3969/j.issn.1001-5256.2021.11.016
Abstract(771) HTML (377) PDF (4249KB)(75)
Abstract:
Objective To investigate the therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride (CCl4)-induced liver fibrosis and its mechanism of action. Methods A total of 24 male C57BL/6 mice were randomly divided into normal group, model group, and Taohong Siwu decoction group...
Risk factors for rebleeding after endoscopic selective variceal devascularization in patients with hepatitis B cirrhosis and acute variceal bleeding
Jiali MA, Yu JIANG, Julong HU, Zhenglin AI, Lingling HE, Yuling ZHOU, Xiuxia LIANG, Yijun LIN, Hongshan WEI, Ping LI
2021, 37(11): 2569-2574. DOI: 10.3969/j.issn.1001-5256.2021.11.017
Abstract(754) HTML (193) PDF (3002KB)(49)
Abstract:
Objective To investigate the rebleeding rate after endoscopic selective variceal devascularization (ESVD) and the predictive factors for rebleeding in patients with hepatitis B cirrhosis and esophageal variceal bleeding (EVB). Methods The patients with hepatitis B cirrhosis and EVB who attended Beij...
Original articles_Liver neoplasms
Value of albumin-bilirubin grade in predicting liver function changes and prognosis of hepatocellular carcinoma patients undergoing transarterial chemoembolization: A Meta-analysis
Weiming YU, Wenqian HONG, Binglun SUN, Jingzhao HAN, Hongfang TUO
2021, 37(11): 2575-2583. DOI: 10.3969/j.issn.1001-5256.2021.11.018
Abstract(1421) HTML (239) PDF (3075KB)(60)
Abstract:
Objective To investigate the value of albumin-bilirubin (ALBI) grade in evaluating liver function changes and prognosis of hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). Methods PubMed, the Cochrane Library, EMbase, Web of Science, OVID, CNKI, Wanfang Data...
Construction of a new patient-derived xenograft model of human liver cancer in mice with normal immunity
Huixin TANG, Shanshan LI, Feng HONG, Yanzhen BI, Quanyi WANG, Xiaobei ZHANG, Shumin CHENG, Zhongping DUAN, Zhenfeng SHU, Yu CHEN
2021, 37(11): 2584-2588. DOI: 10.3969/j.issn.1001-5256.2021.11.019
Abstract(1550) HTML (316) PDF (3030KB)(112)
Abstract:
Objective To establish a new patient-derived xenograft (PDX) model of human liver cancer by inoculating the complex of human primary liver cancer cells and a novel microcarrier (microcarrier 6) into mice with normal immune function. Methods Primary liver cancer cells were isolated and extracted from...
Effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and related mechanism
Xueli YANG, Jianhua XUE, Tianyang CHEN, Jian PING, Tianlu HOU, Jianjie CHEN, Yang CHENG
2021, 37(11): 2589-2594. DOI: 10.3969/j.issn.1001-5256.2021.11.020
Abstract(903) HTML (121) PDF (4218KB)(50)
Abstract:
Objective To investigate the effect of atractylone on the viability and apoptosis of hepatoma HepG2 cells and its mechanism of action. Methods Hepatoma HepG2 cells were selected and divided into low-, middle-, and high-dose atractylone groups (5, 10, and 20 μmol/L), and the cells in the control grou...
Original articles_Other liver diseases
A real-world data analysis of the use of hepatoprotective drugs in outpatients in six cities of China from 2015 to 2019
Zinan ZHAO, Junling LYU, Lei YANG, Yatong ZHANG
2021, 37(11): 2595-2599. DOI: 10.3969/j.issn.1001-5256.2021.11.021
Abstract(722) HTML (186) PDF (2429KB)(121)
Abstract:
Objective To investigate the use of hepatoprotective drugs in China in recent years, and to put forward related suggestions. Methods The outpatient prescription data of hepatoprotective drugs were collected from 85 hospitals in 6 cities of China from 2015 to 2019, and a real-world data analysis was ...
Prevalence rate of non-obese fatty liver disease and related influencing factors
Jiang DENG, Zhiyi HAN, Cailan XIAO, Yating SUN, Yajun JI, Li AO, Yonghong ZHANG, Xiaolan LU
2021, 37(11): 2600-2604. DOI: 10.3969/j.issn.1001-5256.2021.11.022
Abstract(691) HTML (166) PDF (1908KB)(87)
Abstract:
Objective To investigate the prevalence rate of non-obese fatty liver disease and its influencing factors, and to provide a reference for the prevention and treatment of fatty liver disease. Methods A total of 23 545 individuals who underwent physical examination in Karamay Central Hospital from Jan...
A serum metabolomics study on the intervention of nonalcoholic fatty liver disease by equicaloric low-carbohydrate high-protein diet combined with aerobic exercise
Meiying LI, Wanli JI, Wangzhenzu LIU, Tao WANG, Shengnan DU, Jingjing GAO, Yuanye JIANG, Cheng HU
2021, 37(11): 2605-2610. DOI: 10.3969/j.issn.1001-5256.2021.11.023
Abstract(698) HTML (155) PDF (4093KB)(56)
Abstract:
Objective To collect the serum samples of patients with nonalcoholic fatty liver disease (NAFLD), and to investigate the changes in serum metabolic biomarkers before and after lifestyle intervention. Methods A total of 23 patients who were diagnosed with NAFLD in Department of Gastroenterology and I...
Hepatocyte-specific TM6SF2 knockout aggravates hepatic steatosis in mice with nonalcoholic fatty liver disease
Jie ZHANG, Xuefeng MA, Yifen WANG, Mengke WANG, Likun ZHUANG, Shousheng LIU, Yongning XIN
2021, 37(11): 2612-2616. DOI: 10.3969/j.issn.1001-5256.2021.11.024
Abstract(1461) HTML (402) PDF (3743KB)(123)
Abstract:
Objective To establish a mouse model of hepatocyte-specific TM6SF2 knockout, and to investigate the role of TM6SF2 in the development of nonalcoholic fatty liver disease (NAFLD). Methods The CRISPR/Cas9 technique and the Cre/LoxP strategy were used to establish a stable mouse model of hepatocyte-spe...
Clinical features and prognosis of primary myelofibrosis with hepatic vascular disease and/or portal hypertension
Jing WANG, Xiaofeng LIU, Jun TIE
2021, 37(11): 2617-2621. DOI: 10.3969/j.issn.1001-5256.2021.11.025
Abstract(850) HTML (240) PDF (2515KB)(50)
Abstract:
Objective To investigate the clinical features, liver histopathological features, treatment, and prognosis of primary myelofibrosis (PMF)-associated hepatic vascular disease and portal hypertension. Methods A retrospective analysis was performed for the clinical and pathological features of 68 patie...
A preliminary study on percutaneous transhepatic drainage combined with sequential percutaneous nephroscopy in treatment of refractory liver abscess
Changhu DUAN, Xiaochen LIU, Jianlong DING, Jianfeng DUAN, Xirong ZHAO, Fan YANG, Ling WU, Lifei ZHAO, Sheng TAI
2021, 37(11): 2622-2625. DOI: 10.3969/j.issn.1001-5256.2021.11.026
Abstract(558) HTML (102) PDF (2925KB)(35)
Abstract:
Objective To investigate the clinical effect of percutaneous transhepatic drainage combined with sequential percutaneous nephroscopy for necrosectomy and drainage in the treatment of refractory liver abscess after transcatheter arterial embolization (TACE). Methods A retrospective analysis was perfo...
Establishment and evaluation of a nomogram for predicting post-hepatectomy complications in two types of hepatic echinococcosis
Bing GUO, Mingquan PANG, Xiaolei XU, Junwei HAN, Haijiu WANG
2021, 37(11): 2626-2631. DOI: 10.3969/j.issn.1001-5256.2021.11.027
Abstract(551) HTML (109) PDF (2502KB)(24)
Abstract:
Objective To establish a nomogram for predicting the risk of post-hepatectomy complications (PHC) in hepatic echinococcosis by analyzing the risk factors for PHC in two types of hepatic echinococcosis, and to investigate its value in clinical practice. Methods A retrospective analysis was performed ...
Original articles_Biliary diseases
Endoscopic ultrasound features of distal biliary stricture
Hongye LI, Yarong WEI, Huihui LI, Hao DING, Jianglong HONG, Hailun MENG, Zhangwei XU, Junjun BAO, Qiao MEI
2021, 37(11): 2632-2635. DOI: 10.3969/j.issn.1001-5256.2021.11.028
Abstract(668) HTML (405) PDF (1888KB)(46)
Abstract:
Objective To investigate the endoscopic ultrasound (EUS) features of distal biliary stricture (DBS), and to provide a clinical basis for the evaluation of DBS by EUS. Methods Related clinical data were collected from 175 patients with DBS who underwent EUS examination in The First Affiliated Hospita...
Effectiveness and safety of two-step percutaneous transhepatic choledochoscopic lithotomy in treatment of complex hepatolithiasis
Changhu DUAN, Xiaochen LIU, Jianfeng DUAN, Jianlong DING, Xirong ZHAO, Fan YANG, Lin WU, Lifei ZHAO, Sheng TAI
2021, 37(11): 2636-2641. DOI: 10.3969/j.issn.1001-5256.2021.11.029
Abstract(584) HTML (424) PDF (1978KB)(57)
Abstract:
Objective To investigate the clinical effect of two-step percutaneous transhepatic choledochoscopic lithotomy (PTCSL) in the treatment of complex hepatolithiasis. Methods A retrospective analysis was performed for the clinical data of 118 patients with complex hepatolithiasis who were admitted to 32...
Case reports
A case of secondary hemochromatosis with subacute hepatic failure
Sansan YANG, Anhai CHEN
2021, 37(11): 2642-2643. DOI: 10.3969/j.issn.1001-5256.2021.11.030
Abstract(425) HTML (71) PDF (1858KB)(49)
Abstract:
Liver biopsy diagnosis of hepatic extramedullary hematopoiesis: A case report
Lilin JIANG, Juanjuan FU, Linxin TANG, Zhi WANG, Zhonghua LU
2021, 37(11): 2644-2645. DOI: 10.3969/j.issn.1001-5256.2021.11.031
Abstract(639) HTML (329) PDF (2617KB)(43)
Abstract:
A case of hepatic angiosarcoma with Kasabach-Merritt syndrome
Mengnan LI, Gongchen WANG, Zhiming ZHANG
2021, 37(11): 2646-2648. DOI: 10.3969/j.issn.1001-5256.2021.11.032
Abstract(481) HTML (124) PDF (2149KB)(31)
Abstract:
Surgical resection of liver metastases of ovarian cancer and the affected diaphragm and lung lobes via the intercostal approach: A case report
Daqun LIU, Ziyue WANG, Yushi CAO, Xing LYU, Guoyue LYU
2021, 37(11): 2649-2650. DOI: 10.3969/j.issn.1001-5256.2021.11.033
Abstract(466) HTML (319) PDF (2420KB)(18)
Abstract:
A case of huge intrahepatic biliary papillomatosis
Ziyue WANG, Daqun LIU, Jiaao YU, Jingxuan ZHANG, Guoyue LYU
2021, 37(11): 2651-2652. DOI: 10.3969/j.issn.1001-5256.2021.11.034
Abstract(446) HTML (127) PDF (2663KB)(27)
Abstract:
Complete rupture of the pancreas and duodenum caused by car accident in children: A case report
Lijian YANG, Honglai XU, Yuelong HUANG, Xueli LI, Xiubing CHEN
2021, 37(11): 2653-2654. DOI: 10.3969/j.issn.1001-5256.2021.11.035
Abstract(479) HTML (254) PDF (2032KB)(23)
Abstract:
A case of primary splenic angiosarcoma
Huijun WANG, Jianxiang NIU, Xiaoyan XU, Weihua ZHENG, Pengfei LI, Yibo LIU, Junjing ZHANG
2021, 37(11): 2655-2657. DOI: 10.3969/j.issn.1001-5256.2021.11.036
Abstract(432) HTML (187) PDF (3488KB)(41)
Abstract:
Reviews
Mechanism of taurocholic acid in promoting the progression of liver cirrhosis
Yingbiao YUE, Kunhua WANG, Lei ZOU
2021, 37(11): 2658-2662. DOI: 10.3969/j.issn.1001-5256.2021.11.037
Abstract(1335) HTML (181) PDF (3064KB)(99)
Abstract:
Bile acid is the main component of bile, and the external secretion of bile acid into the intestine can help with the absorption of lipids and fat-soluble vitamins; in addition, bile acid acts as a signal molecule to regulate bile acid metabolism and help maintain intestinal homeostasis. The process...
Role of erythropoietin-producing hepatocyte receptors in the pathogenesis of liver fibrosis and hepatocellular carcinoma
Weizhao TONG, wei LIU, Guoxin HU
2021, 37(11): 2663-2666. DOI: 10.3969/j.issn.1001-5256.2021.11.038
Abstract(822) HTML (441) PDF (2646KB)(48)
Abstract:
Erythropoietin-producing hepatocyte (Eph) receptors are the largest subgroup of the receptor tyrosine kinase family and are involved in the physiological processes such as embryonic development, angiogenesis, and axon guidance. Recent studies have shown that Eph receptors are overexpressed in liver ...
Impact of nonalcoholic fatty liver disease on intestinal immune cells
Yalan LEI, Jian BI, Jingwei MAO
2021, 37(11): 2667-2671. DOI: 10.3969/j.issn.1001-5256.2021.11.039
Abstract(571) HTML (101) PDF (1908KB)(38)
Abstract:
Nonalcoholic fatty liver disease (NAFLD) interacts with the intestinal immune system due to enterohepatic circulation and immune cell recruitment and recirculation. Intestinal immune imbalance promotes liver inflammation and fibrosis in the process of NAFLD, and meanwhile, NAFLD can cause disorders ...
Research advances in the association between nonalcoholic fatty liver disease and colorectal adenomatous polyps
Jinhong TANG, Long WANG
2021, 37(11): 2672-2675. DOI: 10.3969/j.issn.1001-5256.2021.11.040
Abstract(513) HTML (186) PDF (1892KB)(44)
Abstract:
Nonalcoholic fatty liver disease (NAFLD) and colorectal adenomatous polyps are closely associated with the various components of metabolic syndrome. This article summarizes the recent studies on the association between NAFLD and colorectal adenomatous polyps, and the results show that NAFLD is assoc...
Effect of diet-gut microbiota axis on nonalcoholic fatty liver disease
Shenglan ZENG, Rongzhen ZHANG, Na WANG, Tingshuai WANG, Liting TAN, Dewen MAO
2021, 37(11): 2676-2679. DOI: 10.3969/j.issn.1001-5256.2021.11.041
Abstract(661) HTML (115) PDF (1900KB)(56)
Abstract:
The incidence rate of nonalcoholic fatty liver disease (NAFLD) is increasing. Diet is considered one of the main driving forces regulating the composition of intestinal microbiota, and the intestine and the liver are closely linked through the portal vein, so changes in gut microbiota may affect liv...
Role of angiopoietin-like proteins in the development of nonalcoholic fatty liver disease
Peiyu ZHENG, Xiuqin AN, Jinchun LIU
2021, 37(11): 2680-2683. DOI: 10.3969/j.issn.1001-5256.2021.11.042
Abstract(644) HTML (294) PDF (2088KB)(40)
Abstract:
Angiopoietin-like proteins (ANGPTLs) are a family of secretory glycoproteins recently found to be constitutionally homologous with angiogenin and play a role in the regulation of angiogenesis. In recent years, more and more studies have shown that ANGPTLs play an important role in glucose and lipid ...
Value of circular RNA in the diagnosis and treatment of nonalcoholic fatty liver disease
Shengnan DU, Jingjing GAO, Tao WANG, Yuanye JIANG, Qin CAO
2021, 37(11): 2684-2688. DOI: 10.3969/j.issn.1001-5256.2021.11.043
Abstract(724) HTML (150) PDF (1904KB)(55)
Abstract:
The prevalence rate of nonalcoholic fatty liver disease (NAFLD) is increasing year by year and it has become one of the most common chronic liver diseases in the world. Studies have shown that circular RNA (circRNA) is closely associated with NAFLD and is considered a potential diagnostic biomarker ...
Mechanism of autophagy in the development and progression of autoimmune hepatitis
Peiwei YANG, Guangwei LIU, Wenxia ZHAO
2021, 37(11): 2689-2691. DOI: 10.3969/j.issn.1001-5256.2021.11.044
Abstract(505) HTML (114) PDF (1883KB)(33)
Abstract:
Autophagy is a process of self-defense and self-repair of cells and tissues and plays an important role in regulating the body's immune inflammatory response and maintaining the homeostasis of liver cells. This article summarizes the mechanism of autophagy in the development and progression of autoi...
Association between myostatin and sarcopenia in end-stage liver disease
Qin ZHAO, Junjie YANG, Yanping ZHONG, Shan LI, Yuanyuan LIU, Xu LEI, Long LIU, Huabing TAN
2021, 37(11): 2692-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.045
Abstract(643) HTML (316) PDF (1890KB)(50)
Abstract:
Patients with end-stage liver disease (ESLD) are often accompanied by various complications such as sarcopenia and cachexia including lipopenia, and it was believed in the past that such status was associated with malnutrition, while recent studies have shown that myostatin (MSTN) is associated with...
Immunotherapy for acute-on-chronic liver failure
Xiaobin QIN, Rongzhen ZHANG, Cong WU, Shenglan ZENG, Yingyu LE, Dewen MAO
2021, 37(11): 2696-2700. DOI: 10.3969/j.issn.1001-5256.2021.11.046
Abstract(661) HTML (183) PDF (1909KB)(63)
Abstract:
Acute-on-chronic liver failure (ACLF) is a life-threatening disease with a high risk of multiple organ failure, sepsis, and death. ACLF activates innate and acquired immune responses in human body and thus leads to the progression of persistent systemic inflammatory response syndrome and multiple or...
Current status of research on the prognostic markers for acute-on-chronic liver failure
Jian LI, Yaqiu DU, Dezhao LI, Huifan JI, Chenggang ZHANG, Qingxia LIU, Xiaolin GUO
2021, 37(11): 2701-2705. DOI: 10.3969/j.issn.1001-5256.2021.11.047
Abstract(576) HTML (291) PDF (1916KB)(61)
Abstract:
Acute-on-chronic liver failure (ACLF) is a syndrome characterized by multiple organ failure and high short-term mortality rate, and it has always been a research hotspot in the field of severe liver diseases. Therefore, early and accurate risk stratification and timely intervention are of great sign...
Role of alpha-fetoprotein in prognostic evaluation of patients with liver failure
Hong WU, Hao LI, Shanhong TANG
2021, 37(11): 2706-2709. DOI: 10.3969/j.issn.1001-5256.2021.11.048
Abstract(1028) HTML (415) PDF (1903KB)(107)
Abstract:
China is a big country with liver diseases, and various hepatitis viruses, drug poisons, and alcohol can cause liver injury and even liver failure. The key to the prognosis of patients with liver failure is liver self-repair and regeneration. Alpha-fetoprotein (AFP) has been extensively studied as a...
Research advances in the association between liver failure and intestinal barrier injury
Lingyan XIAO, Awen XING, Shanzhong TAN
2021, 37(11): 2710-2714. DOI: 10.3969/j.issn.1001-5256.2021.11.049
Abstract(690) HTML (209) PDF (1911KB)(52)
Abstract:
Liver failure and intestinal barrier injury, especially intestinal microflora imbalance, interacts as both the cause and effect of each other. Intestinal barrier injury is observed during liver failure, including the injuries of chemical, mechanical, immune, and microbial barriers, and meanwhile, gu...
Role of Y-box binding protein-1 in the development and progression of chronic liver diseases
Ting LIU, Xiaoli XIE, Huiqing JIANG
2021, 37(11): 2715-2718. DOI: 10.3969/j.issn.1001-5256.2021.11.050
Abstract(533) HTML (170) PDF (1943KB)(24)
Abstract:
Chronic liver diseases have various etiologies and often have poor long-term prognosis in clinical practice. Y-box binding protein-1 (YB-1) is a multifunctional protein, and in-depth studies in recent studies have found that it plays a key role in the development and progression of chronic liver dis...
Role of N6-methyladenosine methylation in liver diseases
Yanzhen MA, Furong WU, Jiafu ZHANG, Chang FAN, Shaopeng HUANG, Sen CHEN, Hui JIANG
2021, 37(11): 2719-2722. DOI: 10.3969/j.issn.1001-5256.2021.11.051
Abstract(676) HTML (199) PDF (2093KB)(50)
Abstract:
N6-methyladenosine (m6A) is a chemical modification that exists in a variety of RNAs and is most commonly observed in mRNA. The liver is a vital metabolic and digestive organ in human body, and m6A methylation plays an important role in the physiological and pathological processes of the liver. This...
Association between genotype and phenotype of ABCB4 gene mutation
Yuhang WENG, Yongfeng YANG
2021, 37(11): 2723-2726. DOI: 10.3969/j.issn.1001-5256.2021.11.052
Abstract(929) HTML (364) PDF (1937KB)(82)
Abstract:
ABCB4-related disease is the syndrome of bile secretion disorder caused by gene mutations and can cause bile duct injury, portal hypertension, and liver cirrhosis in clinical practice. With the development of genetics and gene sequencing techniques in recent years, more and more mutation sites have ...
Advances in the treatment of acute intermittent porphyria
Ru LI, Yi REN, Jianhong WANG, Jing YANG
2021, 37(11): 2728-2731. DOI: 10.3969/j.issn.1001-5256.2021.11.053
Abstract(1174) HTML (731) PDF (2834KB)(132)
Abstract:

Acute intermittent porphyria (AIP) is a rare disease caused by enzyme deficiency due to HMBS gene mutation and is often life-threatening during acute attack. This article introduces the traditional treatment methods for AIP, such as high-carbohydrate therapy and intravenous heme infusion, as well as...
Current status of the application of robot-assisted laparoscopic hepatectomy
Lei WANG, Kangwei LIU, Yuling DUAN, Xinyao LI, Cijun PENG
2021, 37(11): 2732-2736. DOI: 10.3969/j.issn.1001-5256.2021.11.054
Abstract(715) HTML (142) PDF (1918KB)(47)
Abstract:
Robot-assisted laparoscopy hepatectomy (RALH) is a new technique for surgical operation. Compared with conventional laparoscopic hepatectomy, RALH is more frequently used in complex liver tumor and liver tumor with special locations, but this technique is still under development and is limited by th...
Current status of endoscopic diagnosis and treatment of benign biliary stricture
Wencong YUAN, Qiao HE, Zhixin WANG, Haining FAN, Haijiu WANG, Bin REN, Li REN
2021, 37(11): 2737-2741. DOI: 10.3969/j.issn.1001-5256.2021.11.055
Abstract(863) HTML (394) PDF (1910KB)(53)
Abstract:
Benign biliary stricture (BBS) refers to complete or incomplete stricture of the biliary tract caused by a series of non-malignant diseases. BBS often has complex and diverse etiologies, and severe complications may occur if it is not adequately treated. Diagnostic methods currently used in clinical...
Research advances in surgical margin of hilar cholangiocarcinoma
Yirui WANG, Shuochen LIU, Xiangcheng LI
2021, 37(11): 2742-2744. DOI: 10.3969/j.issn.1001-5256.2021.11.056
Abstract(992) HTML (725) PDF (1881KB)(65)
Abstract:
Hilar cholangiocarcinoma (HCCA) is the most common biliary malignancy, and surgical operation is the only possible treatment method at present. The nature of surgical margin is an important influencing factor for the long-term survival of patients, and radical resection can bring great survival bene...
    

The first journal specializing in hepatobiliary and pancreatic diseases in China

Supervisor：Ministry of Education of the People's Republic of China

Sponsor：Jilin University

Academic Support: Chinese Society of Hepatology，Chinese Medical Association

Address: 461 Xinjiang Road, Changchun

Submit：0431-88782044

Peer review：0431-88783542

Email：lcgdb@vip.163.com

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

YesterdayIP[2389]YesterdayPV[5285]TodayIP[724]TodayPV[1357]Online[101]

Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd